The Significance of Enzyme and Transporter Polymorphisms for Imatinib Plasma Levels and Achieving an Optimal Response in Chronic Myeloid Leukemia Patients

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2018 Nov 6

PMID 30393497

Citations 8

Authors

Petra Belohlavkova

Filip Vrbacky

Jaroslava Voglova

Zdenek Racil

Daniela Zackova

Katerina Hrochova

Jana Malakova

Jiri Mayer

Pavel Zak

Affiliations

Soon will be listed here.

Abstract

Introduction: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes.

Material And Methods: In the present study we evaluated the association of eight polymorphisms in the seven genes CYP3A5*3 (rs776746), CYP3A4*1 (rs2740574), CYP2C9*3 (rs1057910), SLC22A1 (rs683369), ABCB1 (rs1045642, rs1128503), ABCG2 (rs2231142) and ABCC2 (rs717620) with imatinib plasma level and achieving an optimal clinical response in 112 CML patients (53 men and 59 women).

Results: No association was found between the examined polymorphisms in rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 and the achieved imatinib plasma level. The influence of rs776746 (CYP3A5*3) on the achievement of a complete cytogenetic response (CCyR) at 6 months was borderline non-significant ( = 0.06). Furthermore, no association was demonstrated between rs776746 polymorphisms and the achievement of a major molecular response (MMR) at 12 or 18 months. Polymorphisms rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 showed no impact on the optimal therapeutic response.

Conclusions: Despite the results of some other studies, no other polymorphism we analyzed was associated with imatinib plasma level or clinical response. The treatment outcomes cannot be predicted using the candidate gene approach and treatment decisions cannot be made according to the polymorphisms investigated in this study.

Citing Articles

Analysis of major otosclerosis-associated variants in and genes in Polish patients.

Ozieblo D, Domagala S, Leja M, Skarzynski H, Oldak M Arch Med Sci. 2024; 20(3):962-966.

PMID: 39050165 PMC: 11264066. DOI: 10.5114/aoms.2020.99011.

Association of polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients.

Asadov C, Karimova N, Hasanova A, Bayramov B, Shirinova A, Alimirzoyeva Z Indian J Med Res. 2023; 158(2):151-160.

PMID: 37706370 PMC: 10645035. DOI: 10.4103/ijmr.ijmr_1103_22.

Impact of and Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis.

Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R Int J Mol Sci. 2023; 24(4).

PMID: 36834713 PMC: 9963452. DOI: 10.3390/ijms24043303.

A systematic review and meta-analysis of the association between HOTAIR polymorphisms and susceptibility to breast cancer.

Wang B, Yuan F, Zhang F, Miao Z, Jiang D Arch Med Sci. 2023; 19(1):128-137.

PMID: 36817654 PMC: 9897084. DOI: 10.5114/aoms.2019.87537.

MiR-146a and miR-155 polymorphisms in Egyptian patients with Behcet's disease.

Shaker O, Abdelaleem O, Fouad N, Ahmed N, Hussein H, Ibrahem E Arch Med Sci. 2022; 18(6):1467-1474.

PMID: 36457982 PMC: 9710268. DOI: 10.5114/aoms/105349.

References

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M . Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2012; 98(2):193-200. PMC: 3561425. DOI: 10.3324/haematol.2012.066480. View

Kim D, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K . Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009; 15(14):4750-8. DOI: 10.1158/1078-0432.CCR-09-0145. View

Peng B, Lloyd P, Schran H . Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005; 44(9):879-94. DOI: 10.2165/00003088-200544090-00001. View

Wang J, Liu H, Li F, Yang W, Wang J, Tan S . Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia. Genet Mol Res. 2015; 14(4):14967-78. DOI: 10.4238/2015.November.24.4. View

Mrozikiewicz-Rakowska B, Malinowski M, Nehring P, Bartkowiak-Wieczorek J, Bogacz A, Zurawinska-Grzelka E . The MDR1/ABCB1 gene rs 1045642 polymorphism in colorectal cancer. Arch Med Sci. 2020; 16(1):112-117. PMC: 6963158. DOI: 10.5114/aoms.2017.70329. View

Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14):2381-8. PMC: 6366340. DOI: 10.1200/JCO.2009.26.3087. View

Seong S, Lim M, Sohn S, Moon J, Oh S, Kim B . Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol. 2012; 24(3):756-60. DOI: 10.1093/annonc/mds532. View

Apperley J . Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(12):1116-1128. DOI: 10.1016/S1470-2045(07)70379-0. View

10.

M L Bedewy A, El-Maghraby S . Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?. Hematology. 2013; 18(4):211-6. DOI: 10.1179/1607845412Y.0000000067. View

11.

Apperley J . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11):1018-29. DOI: 10.1016/S1470-2045(07)70342-X. View

12.

de Lavallade H, Apperley J, Khorashad J, Milojkovic D, Reid A, Bua M . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20):3358-63. DOI: 10.1200/JCO.2007.15.8154. View

13.

Hosseini M, Houshmand M, Ebrahimi A . MTHFR polymorphisms and breast cancer risk. Arch Med Sci. 2012; 7(1):134-7. PMC: 3258688. DOI: 10.5114/aoms.2011.20618. View

14.

Takahashi N, Miura M, Scott S, Kagaya H, Kameoka Y, Tagawa H . Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet. 2010; 55(11):731-7. DOI: 10.1038/jhg.2010.98. View

15.

Bruhn O, Cascorbi I . Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014; 10(10):1337-54. DOI: 10.1517/17425255.2014.952630. View

16.

Cortes J, Egorin M, Guilhot F, Molimard M, Mahon F . Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009; 23(9):1537-44. DOI: 10.1038/leu.2009.88. View

17.

Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-84. PMC: 4915804. DOI: 10.1182/blood-2013-05-501569. View

18.

Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi N . Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol. 2015; 37(1):791-8. DOI: 10.1007/s13277-015-3874-4. View

19.

Au A, Baba A, Goh A, Fadilah S, Teh A, Rosline H . Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother. 2014; 68(3):343-9. DOI: 10.1016/j.biopha.2014.01.009. View

20.

Zhai X, Wang H, Zhu X, Miao H, Qian X, Li J . Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci. 2012; 8(4):659-71. PMC: 3460503. DOI: 10.5114/aoms.2012.30290. View